NRx Pharmaceuticals And Nephron Pharmaceuticals Have Signed An Agreement To Manufacture A Presentation Of Ketamine Suitable For Treating Suicidal Depression; Partners Aim To Submit A New Drug Application By March 1, 2024
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals and Nephron Pharmaceuticals have signed an agreement to manufacture a version of Ketamine for treating suicidal depression. The partners aim to submit a New Drug Application by March 1, 2024, and target a finished drug with two-year shelf stability for November 2024, pending FDA approval.
November 06, 2023 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NRx Pharmaceuticals' partnership with Nephron Pharmaceuticals to produce a new form of Ketamine could potentially boost its stock, pending successful FDA approval and market reception.
The partnership with Nephron Pharmaceuticals to produce a new form of Ketamine for treating suicidal depression could potentially boost NRx Pharmaceuticals' stock. This is contingent on successful FDA approval and market reception of the drug. However, as the New Drug Application is targeted for March 2024, any potential impact on the stock will likely not be immediate.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100